On December 3, 2020 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, reported that it will be participating in the Benzinga Global Small Cap Conference being held virtually on December 8 and 9, 2020 (Press release, Citius Pharmaceuticals, DEC 3, 2020, https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-corporate-update-at-benzinga-global-small-cap-conference-on-december-8-301186114.html [SID1234572149]). Citius Chairman Leonard Mazur will present at 11:30 am ET on Tuesday, December 8, 2020, and will host one-on-one investor meetings.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Advanced investor registration for the conference and virtual one-to-one meeting requests can be accessed here.
We are currently advancing four proprietary product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation or Halo-Lido), CITI-101 (Mino-Wrap), and CITI-401 (iMSC). Mr. Mazur will discuss recent Company developments for these product candidates including:
Mino-Lok is advancing in its Phase 3 trial
A positive second interim analysis report from the independent Drug Monitoring Committee (DMC) for the Mino-Lok pivotal Phase 3 trial
The signing of an exclusive worldwide license agreement with Novellus Therapeutics, Limited for a cellular therapy to treat acute respiratory distress syndrome (ARDS), a leading complication of COVID-19; and the formation of our Novecite, Inc. subsidiary.
Submission of a pre-investigational new drug (PIND) consultation request for Mino-Wrap with written response and guidance is expected
Update on Halo-Lido which is anticipated to begin Phase 2b trial in the first quarter of 2021